1. Carl Haney appointed as Chief R&D Officer, effective August 2025. 2. Haney brings 13 years of experience from Estée Lauder. 3. CEO praises Haney's transformational innovation expertise for Haleon's growth. 4. Outgoing Franck Riot's contributions recognized following his departure. 5. Haleon aims to leverage R&D for consumer health innovation.
The appointment of a high-profile R&D leader may enhance innovation, supporting Haleon's growth strategy. Similar past cases in consumer health led to stock price increases due to innovation boosts.
Carl Haney's extensive background in R&D could significantly influence Haleon's innovation trajectory and market competitiveness, making this news impactful.
The effects of leadership changes in R&D typically take time to materialize in product innovation and market performance, potentially observed over several quarters.
Haleon (LSE: HLN) (NYSE: HLN) today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025.
This appointment follows Franck Riot deciding to leave Haleon after six years in the business.
Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care.
"I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon's significant potential through our new Win as One strategy.
"I want to take this opportunity to thank Franck for his significant contribution to Haleon over the last six years. He has played an important role in the lead up to and beyond separation to move our innovation agenda forward and prepare us for the next phase of our journey. On behalf of everyone at Haleon, I wish him the very best for the future."
"I am hugely excited to be joining Haleon at such an important stage of its journey, as it looks to capitalise on the significant opportunities ahead and continues its transformation into a world class consumer company. I am incredibly passionate about the role that R&D can play in delivering Haleon's ambitions and its purpose of delivering better everyday health with humanity. I am very much looking forward to meeting the team and getting started in August."
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
Photo - https://mma.prnewswire.com/media/2717039/Haleon.jpg
SOURCE Haleon
